This week, we look at using the, marginally effective, Covid treatment, remdesivir in patients with decreased GFR against the advice of the manufacturer and the FDA.
Visual abstract for the Remdesivir in AKI study
Thank-you Dhwanil Patel for the excellent visual abstract for this week’s NephJC Chat